Industry
Biotechnology
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Loading...
Open
3.18
Mkt cap
40M
Volume
68K
High
3.20
P/E Ratio
-0.19
52-wk high
20.00
Low
2.94
Div yield
N/A
52-wk low
2.57
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.